GlassScriptPhysician profile
Alan M Mermelstein
NPI 1073520458
$5,121.74
in general payments reported to CMS, 2019-2025
37 companies · $923 in 2025
The $923 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $552 · 2020: $569 · 2021: $726 · 2022: $341 · 2023: $586 · 2024: $1,425 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,893 · Education: $40.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,892.89 |
| Education | $40.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $926.63 | 2019-2025 | |
| Abbvie INC. | $855.66 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $549.27 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $287.59 | 2020-2025 | Entyvio |
| Genzyme Corporation | $210.99 | 2022-2025 | |
| Novo Nordisk INC | $191.67 | 2019-2023 | Wegovy |
| Janssen Biotech, INC. | $186.96 | 2024-2025 | Tremfya, Simponi, Simponi Aria |
| Qol Medical, LLC | $181.10 | 2025 | Sucraid |
| Avanir Pharmaceuticals, INC. | $177.96 | 2019-2021 | |
| Ardelyx, INC. | $161.40 | 2022-2025 | Ibsrela |
| Amarin Pharma, INC. | $154.26 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $135.10 | 2024-2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $134.85 | 2019-2024 | Linzess |
| Lilly USA, LLC | $134.42 | 2019-2025 | Omvoh |
| Sun Pharmaceutical Industries INC. | $100.04 | 2020-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $81.05 | 2021-2023 | Repatha, Otezla |
| Pfizer INC. | $79.50 | 2023-2024 | |
| Celgene Corporation | $78.90 | 2022-2023 | Zeposia |
| Shield Therapeutics INC | $63.65 | 2024 | |
| Intercept Pharmaceuticals, INC. | $63.23 | 2020-2025 | |
| Ultragenyx Pharmaceutical INC. | $54.77 | 2021-2022 | |
| Celltrion USA INC. | $37.30 | 2024-2025 | Zymfentra, Vegzelma |
| Sanofi Pasteur INC. | $27.92 | 2019-2020 | |
| Erbe USA INC | $27.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.89 | 2020 | |
| Phathom Pharmaceuticals, INC. | $21.58 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $21.52 | 2023 | Arexvy |
| Janssen Pharmaceuticals, INC | $19.87 | 2019 | |
| Allergan, INC. | $19.19 | 2020 | |
| Evoke Pharma, INC. | $17.74 | 2024 | |
| Daiichi Sankyo INC. | $16.15 | 2019 | |
| Bausch Health US, LLC | $15.90 | 2021 | |
| Ucb, INC. | $15.73 | 2021 | |
| Lundbeck LLC | $13.03 | 2023 | Rexulti |
| Merck Sharp & Dohme LLC | $12.06 | 2019 | |
| Seqirus USA INC | $11.48 | 2020 | |
| Alfasigma USA, INC. | $11.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Mermelstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.